pneumococcal 23-valent polysaccharide vaccine

**Pneumococcal 23-valent polysaccharide vaccine** is a non-conjugated multivalent bacterial vaccine composed of purified capsular polysaccharides from 23 *Streptococcus pneumoniae* serotypes. It elicits serotype-specific humoral antibodies that promote opsonization and phagocytic clearance of pneumococci, helping prevent pneumococcal disease, including invasive disease manifestations such as bacteremia and meningitis. The composition-defined vaccine category is marketed as products including Merck's Pneumovax 23 and Sanofi's Pneumo 23; the U.S. licensed Pneumovax 23 product is indicated for prevention of disease caused by its 23 included serotypes in adults aged 50 years and older and in people aged 2 years and older at increased risk. ([fda.gov](https://www.fda.gov/vaccines-blood-biologics/vaccines/pneumovax-23-pneumococcal-vaccine-polyvalent))

Brand names

Pneumovax 23Pneumovax23Pneumovax-23Pneumo 23Pneumo23Pneumo-23

Other names

PPSV23PPSV-23PPSV 23PPV23PPV-23PPV 2323-valent pneumococcal polysaccharide vaccinepneumococcal vaccine polyvalent